Matthew V. Sennitt

1.8k total citations · 1 hit paper
22 papers, 1.6k citations indexed

About

Matthew V. Sennitt is a scholar working on Physiology, Molecular Biology and Animal Science and Zoology. According to data from OpenAlex, Matthew V. Sennitt has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Physiology, 10 papers in Molecular Biology and 6 papers in Animal Science and Zoology. Recurrent topics in Matthew V. Sennitt's work include Adipose Tissue and Metabolism (18 papers), Pharmacological Effects and Assays (6 papers) and Peroxisome Proliferator-Activated Receptors (4 papers). Matthew V. Sennitt is often cited by papers focused on Adipose Tissue and Metabolism (18 papers), Pharmacological Effects and Assays (6 papers) and Peroxisome Proliferator-Activated Receptors (4 papers). Matthew V. Sennitt collaborates with scholars based in United Kingdom, Switzerland and United States. Matthew V. Sennitt's co-authors include Michael A. Cawthorne, Jonathan R.S. Arch, Shelagh Wilson, Campbell Wilson, Valerie Piercy, Véronique Converset, Denis F. Hochstrasser, Steven Wang, G. M. Schmid and Jacqueline O’Dowd and has published in prestigious journals such as Nature, Diabetes and Biochemical and Biophysical Research Communications.

In The Last Decade

Matthew V. Sennitt

22 papers receiving 1.5k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs

1984 615 citations Jonathan R.S. Arch, Michael A. Cawthorne et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew V. Sennitt United Kingdom	17	868	756	340	221	195	22	1.6k
Valerie Piercy United Kingdom	10	711 0.8×	464 0.6×	284 0.8×	122 0.6×	190 1.0×	15	1.3k
Stéphane Krief France	19	1.1k 1.3×	928 1.2×	243 0.7×	209 0.9×	187 1.0×	32	2.1k
Takahiro Horinouchi Japan	23	531 0.6×	845 1.1×	145 0.4×	59 0.3×	286 1.5×	96	1.5k
E. Bergamini Italy	24	474 0.5×	616 0.8×	44 0.1×	292 1.3×	98 0.5×	89	1.7k
Maria Neverova United States	5	1.6k 1.8×	760 1.0×	50 0.1×	383 1.7×	50 0.3×	5	1.9k
Lois M. Zucker United States	10	817 0.9×	327 0.4×	81 0.2×	119 0.5×	88 0.5×	15	1.4k
Sonia Samec Switzerland	20	2.5k 2.9×	1.1k 1.5×	96 0.3×	909 4.1×	58 0.3×	25	2.9k
Olof A. Forsander Finland	20	336 0.4×	368 0.5×	64 0.2×	111 0.5×	314 1.6×	52	1.4k
V.G. Wilson United Kingdom	24	667 0.8×	871 1.2×	85 0.3×	26 0.1×	510 2.6×	83	2.0k
C. E. Mondon United States	25	1.2k 1.4×	1.1k 1.4×	48 0.1×	486 2.2×	94 0.5×	52	2.8k

Countries citing papers authored by Matthew V. Sennitt

Since Specialization

Citations

This map shows the geographic impact of Matthew V. Sennitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew V. Sennitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew V. Sennitt more than expected).

Fields of papers citing papers by Matthew V. Sennitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew V. Sennitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew V. Sennitt. The network helps show where Matthew V. Sennitt may publish in the future.

Co-authorship network of co-authors of Matthew V. Sennitt

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew V. Sennitt. A scholar is included among the top collaborators of Matthew V. Sennitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew V. Sennitt. Matthew V. Sennitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Wargent, Edward T., Matthew V. Sennitt, Claire J. Stocker, et al.. (2005). Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Lipids in Health and Disease. 4(1). 3–3. 56 indexed citations

2.

Wargent, Edward T., Claire J. Stocker, Petra Augstein, et al.. (2004). Improvement of glucose tolerance in Zucker diabetic fatty rats by long‐term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obesity and Metabolism. 7(2). 170–181. 11 indexed citations

3.

Schmid, G. M., Véronique Converset, Nadia Walter, et al.. (2004). Effect of high‐fat diet on the expression of proteins in muscle, adipose tissues, and liver of C57BL/6 mice. PROTEOMICS. 4(8). 2270–2282. 92 indexed citations

4.

Sanchez, Jean‐Charles, Véronique Converset, Anna L. Nolan, et al.. (2003). Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. PROTEOMICS. 3(8). 1500–1520. 47 indexed citations

5.

Stocker, Claire J., Jacqueline O’Dowd, Nicholas M. Morton, et al.. (2003). Modulation of susceptibility to weight gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin during pregnancy and lactation. International Journal of Obesity. 28(1). 129–136. 74 indexed citations

6.

Sanchez, Jean‐Charles, Véronique Converset, Anna L. Nolan, et al.. (2002). Effect of Rosiglitazone on the Differential Expression of Diabetes-associated Proteins in Pancreatic Islets of C57Bl/6 lep/lep Mice. Molecular & Cellular Proteomics. 1(7). 509–516. 67 indexed citations

7.

Stocker, Claire J., Matthew V. Sennitt, Anna L. Nolan, et al.. (2001). Guggul lipid reduces insulin resistance and body weight gain in C57B1/6 lep/lep mice. 2. 24. 1 indexed citations

8.

Sanchez, Jean‐Charles, Diego Chiappe, Véronique Converset, et al.. (2001). The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and obesity. PROTEOMICS. 1(1). 136–163. 132 indexed citations

9.

Sanchez, Jean‐Charles, Diego Chiappe, Véronique Converset, et al.. (2001). The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and obesity. PROTEOMICS. 1(1). 136–163. 11 indexed citations

10.

Emilsson, Valur, Jacqueline O’Dowd, Steven Wang, et al.. (2000). The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism. 49(12). 1610–1615. 46 indexed citations

11.

Sennitt, Matthew V., Alberto J. Kaumann, Peter Molenaar, et al.. (1998). The contribution of classical (beta1/2-) and atypical beta-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel beta3-adrenoceptor agonists of differing selectivities.. PubMed. 285(3). 1084–95. 53 indexed citations

12.

Sennitt, Matthew V., Alberto J. Kaumann, Peter Molenaar, et al.. (1998). The Contribution of Classical (β1/2-) and Atypical β-Adrenoceptors to the Stimulation of Human White Adipocyte Lipolysis and Right Atrial Appendage Contraction by Novel β3-Adrenoceptor Agonists of Differing Selectivities. Journal of Pharmacology and Experimental Therapeutics. 285(3). 1084–1095. 23 indexed citations

13.

Oriowo, Mabayoje A., et al.. (1996). The selectivity in vitro of the stereoisomers of the beta-3 adrenoceptor agonist BRL 37344.. Journal of Pharmacology and Experimental Therapeutics. 277(1). 22–27. 33 indexed citations

14.

Oriowo, Mabayoje A., Matthew V. Sennitt, Stephen A. Smith, Robert Ruffolo, & Michael A. Cawthorne. (1994). The β‐adrenoceptor selectivity profile of BRL 37344 in the pithed rat. Journal of Autonomic Pharmacology. 14(5). 337–344. 4 indexed citations

15.

Challiss, R. A. John, L Budohoski, Eric A. Newsholme, Matthew V. Sennitt, & Michael A. Cawthorne. (1985). Effect of a novel thermogenic β-adrenoceptor agonist (BRL 26830) on insulin resistance in soleus muscle from obese Zucker rats. Biochemical and Biophysical Research Communications. 128(2). 928–935. 20 indexed citations

16.

Smith, Stephen A., et al.. (1985). Effects of BRL 26830, a novel β-adrenoceptor agonist, on glucose tolerance, insulin sensitivity and glucose turnover in zucker (fa/fa) rats. Biochemical Pharmacology. 34(14). 2425–2429. 25 indexed citations

17.

Sennitt, Matthew V., et al.. (1985). Anti-hyperglycaemic action of BRL 26830, a novel β-adrenoceptor agonist, in mice and rats. Biochemical Pharmacology. 34(8). 1279–1285. 27 indexed citations

18.

Arch, Jonathan R.S., Michael A. Cawthorne, Valerie Piercy, et al.. (1984). Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 309(5964). 163–165. 615 indexed citations breakdown →

19.

Wilson, Campbell, Shelagh Wilson, Valerie Piercy, Matthew V. Sennitt, & Jonathan R.S. Arch. (1984). The rat lipolytic β-adrenoceptor: Studies using novel β-adrenoceptor agonists. European Journal of Pharmacology. 100(3-4). 309–319. 141 indexed citations

20.

Sennitt, Matthew V., et al.. (1982). The effect of 5-methylpyrazole-3-carboxylate and nicotinic acid on abnormalities of carbohydrate metabolism in alloxan-diabetic rat muscle. Biochemical Pharmacology. 31(1). 63–68. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact